bria health services

BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the following updates:

Pursuant to the securities buyback program announced Sept. 9, 2021 , BriaCell has repurchased 202,425 common shares (the "Common Shares") and 70,246 publicly traded BCTXW warrants (the "Listed Warrants"). As announced, BriaCell may purchase through the facilities of the TSX Venture Exchange ("TSXV") or the Nasdaq Capital Market ("Nasdaq") or alternative exchanges (i) up to 1,341,515 Common Shares and (ii) up to 411,962 publicly traded BCTXW Listed Warrants in total, representing 10% of the 13,415,154 Common Shares and 10% of the 4,119,622 Listed Warrants comprising the "public float" as of September 8, 2021, over the next 12 months.

BriaCell is fully-capitalized to achieve its strategic clinical milestones. Because of this BriaCell's Board of Directors believes the best use of a portion of its excess capital at this time is to buy back its own Common Shares and Listed Warrants for cancellation. As of July 31, 2021, BriaCell's cash balance was US$57.3 million which provides the strength and flexibility to execute both the buyback program and BriaCell's growth strategy to expand into previously-announced areas of cancer immunotherapy and/or advance its current breast cancer clinical trials.

Separately, the Company announces that Dr. William V. Williams, President & CEO of BriaCell, is scheduled to present at the following virtual conferences:

  • Q4 Investor Summit: November 16 – 17, 2021
    • Dr. Williams will deliver his corporate presentation at 10:15 a.m. ET on November 16, 2021
    • Investors may register for the conference at: https://investorsummitgroup.com/
    • Investors may request one-on-one meetings with management
    • A public webcast can be accessed via the following link: https://us06web.zoom.us/webinar/register/WN_qK33aeh9TOmLiCnC-GM91w

  • The 2021 San Antonio Breast Cancer Symposium®: December 7 – 10, 2021
    • BriaCell's lead product candidate, Bria-IMT™, will be featured during the following:
      • Poster Session 2: 5:00 - 6:30 p.m. CT on Wednesday, December 8, 2021
      • Presentation Title: Overall Survival Following Treatment with a Modified Whole Tumor Cell Targeted Immunotherapy in Patients with Advanced Breast Cancer
    • The poster presentation will be accessible at a later date at: https://briacell.com/novel-technology/scientific-publications/

  • MedInvest Oncology Conference: December 7 – 10, 2021
    • Dr. Williams will be speaking at the conference at 2:30 p.m. ET on December 7, 2021
    • Investors may register for the conference at: https://www.medinvestconferences.com/
    • Investors may request on-on-one meetings with management

  • Benzinga Global Small Cap Virtual Investor Conference: December 8 – 9, 2021

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/ .

Safe Harbor

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com

Media Relations:
Jules Abraham
Director of Public Relations
CORE IR
917-885-7378
julesa@coreir.com

Investor Relations Contact:
CORE IR
investors@briacell.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)

AMGEN TO PRESENT DATA FROM MULTIPLE EARLY-STAGE CLINICAL TRIALS AT ESMO 2024

Results Illustrate Depth and Diversity of Amgen's Targeted Therapies Across Tumor Types

- Amgen (NASDAQ: AMGN) today announced the presentation of new data across its broad oncology pipeline and portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, taking place Sept. 13-17 in Barcelona . The abstracts showcase data from Amgen-sponsored and investigator-sponsored studies for colorectal, lung, prostate and gastric cancers using molecularly targeted modalities.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024

Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science and medicine on November 18, 2024

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced the data from its Phase II open-label MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis will be reported in an oral presentation as part of the Laennec Clinician-Educator Award & Lecture that runs from 9:45 a.m. to 11:00 a.m. Central Time, on Monday, November 18th, 2024, at the American Heart Association Scientific Sessions 2024. Dr. S. Allen Luis, Co-Director, Pericardial Diseases Clinic and Associate Professor of Medicine, Department of Cardiovascular Medicine at the Mayo Clinic, will present on behalf of the MAvERIC-Pilot investigators.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

AMGEN PRESENTS NEW DATA FOR FIRST-IN-CLASS IMDELLTRA IN SMALL CELL LUNG CANCER AT WCLC 2024

DeLLphi-303 Study Results Show Potential for IMDELLTRA in Combination with a PD-L1 Inhibitor as First-Line Maintenance Therapy in ES-SCLC

DeLLphi-301 Long-Term Follow-up Data Demonstrate Sustained Safety and Efficacy for IMDELLTRA

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 2024 WELLS FARGO HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2024 Wells Fargo Healthcare Conference at 9:30 a.m. ET on Thursday Sept. 5, 2024. Peter Griffith executive vice president and chief financial officer at Amgen, and Jay Bradner executive vice president of Research and Development and chief scientific officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  BPH Global Ltd

Appendix 4E and Preliminary Final Report - For the Year Ended 30 June 2024

BPH Global Limited (ASX: BP8) (“BP8” or the “Company” or the “Group”) has released its Appendix 4E Preliminary Final Report.


Keep reading...Show less
Hydralyte

H1 FY24 Half Year Report and Appendix 4D: 29% Reduction in Net Cash Used in Operating Activities alongside Stable Revenue

Hydration solutions company The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte North America” or “the Company”) is pleased to provide the following update on the six-month period ended 30 June 2024 (the “half year” or “H1 FY2024”) and the Company’s Appendix 4D.

Keep reading...Show less

Latest Press Releases

Related News

×